Literature DB >> 679595

Spironolactone-induced changes in digoxin kinetics.

S Waldorff, J D Andersen, N Heebøll-Nielsen, O G Nielsen, E Moltke, U Sørensen, E Steiness.   

Abstract

Plasma clearance, volumes of distribution, and renal and extrarenal clearances of digoxin were calculated from plasma digoxin concentrations and urinary excretion of digoxin after intravenous injection of digoxin in 8 subjects. The investigation was repeated in the same subjects during long-term treatment with spironolactone. Increased plasma concentration of digoxin was detected during spironolactone treatment. Calculated plasma and renal clearances of digoxin and the volumes of distribution decreased statistically significant. Near maximal capacity for the tubular secretion of digoxin was found when normal digoxin dosage was used. It is suggested that unless spironolactone decreases the myocardial sensitivity for digoxin, the loading dose as well as the maintenance dose of digoxin should be reduced during treatment with spironolactone.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 679595     DOI: 10.1002/cpt1978242162

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  25 in total

1.  Use of different parameters and equations for calculation of IC₅₀ values in efflux assays: potential sources of variability in IC₅₀ determination.

Authors:  Donna A Volpe; Salaheldin S Hamed; Lei K Zhang
Journal:  AAPS J       Date:  2013-12-13       Impact factor: 4.009

Review 2.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 4.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

5.  The acute effects of amiloride and potassium canrenoate on digoxin-induced positive inotropism in healthy volunteers.

Authors:  J P Richter; D K Sommers; J R Snyman; S M Millard
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 6.  Disease-related alterations in cardiac glycoside disposition.

Authors:  H R Ochs; D J Greenblatt; G Bodem; H J Dengler
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

7.  Systolic time intervals during spironolactone treatment of digitalized and non-digitalized patients with ischaemic heart disease.

Authors:  S Waldorff; J Berning; J Buch; E Steiness
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  The long-term effect of verapamil on plasma digoxin concentration and renal digoxin clearance in healthy subjects.

Authors:  K E Pedersen; A Dorph-Pedersen; S Hvidt; N A Klitgaard; K K Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of digoxin 1980.

Authors:  J K Aronson
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

10.  Amiloride improves hemodynamics in patients with chronic congestive heart failure treated with chronic digoxin and diuretics.

Authors:  M D Cheitlin; R Byrd; N Benowitz; E Liu; G Modin
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.